文章基本信息

标题：Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring
本地全文：下载
作者：Denis Horgan ; Tanja Čufer ; Francesco Gatto 等
期刊名称：Healthcare
电子版ISSN：2227-9032
出版年度：2022
卷号：10
期号：9
DOI：10.3390/healthcare10091714
语种：English
出版社：MDPI Publishing
摘要：Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-derived components in body fluids. It provides an alternative to current cancer screening methods that use tissue biopsies for the confirmation of diagnosis. This paper attempts to determine how far the regulatory, policy, and governance framework provide support to LB implementation into healthcare systems and how the situation can be improved. For that reason, the European Alliance for Personalised Medicine (EAPM) organized series of expert panels including different key stakeholders to identify different steps, challenges, and opportunities that need to be taken to effectively implement LB technology at the country level across Europe. To accomplish a change of patient care with an LB approach, it is required to establish collaboration between multiple stakeholders, including payers, policymakers, the medical and scientific community, and patient organizations, both at the national and international level. Regulators, pharma companies, and payers could have a major impact in their own domain. Linking national efforts to EU efforts and vice versa could help in implementation of LB across Europe, while patients, scientists, physicians, and kit manufacturers can generate a pull by undertaking more research into biomarkers.
关键词：enliquid biopsycancerpersonalized medicinetechnologyhealthcarepolicy frameworklegislationdiagnosistreatmentgovernanceimplementation